⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL76020 | 1.00 | — | — | |
| SCHEMBL76021 | 1.00 | — | — | |
| SCHEMBL31468276 | 0.91 | TSHR (0.44) | — | |
| SCHEMBL31468268 | 0.91 | TSHR (0.44) | — | |
| SCHEMBL6411139 | 0.79 | TSHR (0.48) | — | |
| SCHEMBL14997322 | 0.79 | — | — | |
| SCHEMBL359717 | 0.77 | — | — | |
| SCHEMBL16316794 | 0.77 | — | — | |
| SCHEMBL18225 | 0.77 | — | — | |
| SCHEMBL25178226 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115010617-B | Preparation method of iopamidol | 安徽普利药业有限公司 | 2024-06-11 | — | — | CN | claimed |
| CN-115010617-A | Preparation method of iopamidol | 安徽普利药业有限公司 | 2022-09-06 | — | — | CN | claimed |
| EP-4646411-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-4635944-A1 | 2-AZABICYCLO[3.1.1]HEPTANE COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2025-10-22 | — | — | EP | disclosed |
| US-20250122171-A1 | Substituted Amine Compounds, Compositions and Methods of Use | DEEP APPLE THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| WO-2025064535-A1 | TRICYCLIC SUBSTITUTED AMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | DEEP APPLE THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| WO-2025064534-A1 | SUBSTITUTED AMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | DEEP APPLE THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| EP-4479137-A1 | IRAK4 INHIBITORS | Astrazeneca AB (SE) | 2024-12-25 | — | — | EP | disclosed |
| CN-118591536-A | IRAK4 inhibitors | 阿斯利康(瑞典)有限公司 | 2024-09-03 | — | — | CN | disclosed |
| WO-2024148089-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2024128305-A1 | 2-AZABICYCLO[3.1.1]HEPTANE COMPOUND | 第一三共株式会社 | 2024-06-20 | — | — | WO | disclosed |
| WO-2011041399-A2 | PI3K (DELTA) SELECTIVE INHIBITORS | TYROGENEX, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
| EP-2027104-B1 | ARYLSULFONYLCHROMANS AS 5-HT6 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-02-23 | — | — | EP | disclosed |
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-7754759-B2 | Arylsulfonyl chromans as 5-HT6 inhibitors | ROCHE PALO ALTO LLC (US) | 2010-07-13 | — | — | US | disclosed |
| WO-2009065035-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN TREATING DISEASES AND DISORDERS | MYRIAD GENETICS, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
| EP-2027104-A1 | ARYLSULFONYLCHROMANS AS 5-HT6 INHIBITORS INDOLYLMALEIMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-02-25 | — | — | EP | disclosed |
| CN-101300246-A | Arylsulfonylchromans as 5-HT6 inhibitors indolylmaleimide derivatives as protein kinase inhibitors | HOFFMANN LA ROCHE (CH) | 2008-11-05 | — | — | CN | disclosed |
| WO-2007051735-A1 | ARYLSULFONYLCHROMANS AS 5-HT6 INHIBITORS INDOLYLMALEIMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-10 | — | — | WO | disclosed |
| US-20070099908-A1 | Arylsulfonyl chromans as 5-HT6 inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-03 | — | — | US | disclosed |